ReviewCancer research and treatment2026

Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates.

Jiwon Koh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.